Detalhe da pesquisa
1.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739079
2.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
J Card Fail
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493832
3.
CardioScape mapping the cardiovascular funding landscape in Europe.
Eur Heart J
; 39(25): 2423-2430, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449050
4.
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
J Card Fail
; 29(11): 1576-1582, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37473912
5.
Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy.
Eur Heart J
; 34(32): 2529-37, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23455360
6.
A case report of complex congenital heart disease co-existing with hypertrophic cardiomyopathy.
Eur Heart J Case Rep
; 8(2): ytae038, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38313326
7.
Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy.
J Clin Med
; 13(3)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38337535
8.
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
JACC Heart Fail
; 12(1): 199-215, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38032573
9.
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol
; 5(5): 628-637, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37969652
10.
British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.
Echo Res Pract
; 10(1): 13, 2023 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653443
11.
History of the British Cardiovascular Society.
Heart
; 108(10): 761-766, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459725
12.
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
Adv Ther
; 39(6): 2292-2301, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35419651
13.
Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
JAMA Cardiol
; 4(3): 230-235, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30725091
14.
Reply: Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC CardioOncol
; 5(6): 850, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38204997
15.
Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy.
Circ Genom Precis Med
; 11(12): e001974, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30562113
16.
Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease.
Acta Myol
; 36(3): 135-150, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29774304
17.
Arrhythmogenic left ventricular cardiomyopathy.
Circulation
; 120(25): 2613-4, 2009 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20026794
18.
Current applications of biomarkers in cardiomyopathies.
Expert Rev Cardiovasc Ther
; 13(7): 825-37, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26106935
19.
Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy.
Circ Heart Fail
; 8(6): 1022-31, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26374874
20.
Calculated plasma volume status and prognosis in chronic heart failure.
Eur J Heart Fail
; 17(1): 35-43, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25469484